Άρθρα σχετικά με την ατελή οστεογένεση και τα διφωσφωνικά

  1. Land C, Rauch F, Glorieux FH.
    Cyclical intravenous pamidronate treatment affects metaphyseal modeling in
    growing patients with osteogenesis imperfecta.
    J Bone Miner Res. 2006 Mar;21(3):374-9. Epub 2005 Dec 19.
    PMID: 16491284 [PubMed - indexed for MEDLINE]
  2. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F,
    Garnero P, Arlot M, Raynal C, Meunier PJ.
    Effects of oral alendronate on BMD in adult patients with osteogenesis
    imperfecta: a 3-year randomized placebo-controlled trial.
    J Bone Miner Res. 2006 Feb;21(2):300-6. Epub 2005 Oct 24.
    PMID: 16418786 [PubMed - indexed for MEDLINE]
  3. Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson
    TA; LWPES Pharmacy and Therapeutic Committee.
    Bisphosphonate treatment of pediatric bone disease.
    Pediatr Endocrinol Rev. 2005 Dec;3(2):87-96. Review.
    PMID: 16361982 [PubMed - indexed for MEDLINE]
  4. Unal E, Abaci A, Bober E, Buyukgebiz A.
    Oral alendronate in osteogenesis imperfecta.
    Indian Pediatr. 2005 Nov;42(11):1158-60.
    PMID: 16340059 [PubMed - indexed for MEDLINE]
  5. McQuade M, Houghton K.
    Use of bisphosphonates in a case of Perthes disease.
    Orthop Nurs. 2005 Nov-Dec;24(6):393-8.
    PMID: 16319725 [PubMed - indexed for MEDLINE]
  6. Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA.
    Impact of alendronate on quality of life in children with osteogenesis imperfecta.
    J Pediatr Orthop. 2005 Nov-Dec;25(6):786-91.
    PMID: 16294137 [PubMed - indexed for MEDLINE]
  7. Rauch F, Travers R, Glorieux FH.
    Pamidronate in children with osteogenesis imperfecta: histomorphometric effects
    of long-term therapy.
    J Clin Endocrinol Metab. 2006 Feb;91(2):511-6. Epub 2005 Nov 15.
    PMID: 16291701 [PubMed - indexed for MEDLINE]
  8. Naiki Y, Tanaka T.
    [Osteoporosis caused by pediatric diseases]
    Nippon Rinsho. 2005 Oct;63 Suppl 10:572-6. Review. Japanese. No abstract
    available.
    PMID: 16279703 [PubMed - indexed for MEDLINE]
  9. Amarasena S, Lekamwasam S, Jayawardena P.
    Cyclical intravenous pamidronate therapy in children with osteogenesis
    imperfecta.
    Ceylon Med J. 2005 Sep;50(3):137-8. No abstract available.
    PMID: 16252586 [PubMed - indexed for MEDLINE]
  10. Graul AI.
    Filling the gaps: osteogenesis imperfecta.
    Drug News Perspect. 2005 Jul-Aug;18(6):400-1. No abstract available.
    PMID: 16247517 [PubMed - indexed for MEDLINE]
  11. Vyskocil V, Pikner R, Kutilek S.
    Effect of alendronate therapy in children with osteogenesis imperfecta.
    Joint Bone Spine. 2005 Oct;72(5):416-23. Epub 2004 Nov 10.
    PMID: 16214075 [PubMed - indexed for MEDLINE]
  12. Srinivasan R.
    Pamidronate lines.
    Indian Pediatr. 2005 Sep;42(9):959-60. No abstract available.
    PMID: 16208065 [PubMed - indexed for MEDLINE]
  13. Rossi F, Perrotta S, Falcone E, Gimigliano F, Iodice M, Vetrella S,
    Iolascon G.
    [Idiopathic and secondary osteoporosis in childhood]
    Minerva Pediatr. 2005 Oct;57(5):203-11. Review. Italian.
    PMID: 16205605 [PubMed - indexed for MEDLINE]
  14. Cho TJ, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK.
    Efficacy of oral alendronate in children with osteogenesis imperfecta.
    J Pediatr Orthop. 2005 Sep-Oct;25(5):607-12.
    PMID: 16199940 [PubMed - indexed for MEDLINE]
  15. Smith EJ, Little DG, Briody JN, McEvoy A, Smith NC, Eisman JA, Gardiner EM.
    Transient disturbance in physeal morphology is associated with long-term
    effects of nitrogen-containing bisphosphonates in growing rabbits.
    J Bone Miner Res. 2005 Oct;20(10):1731-41. Epub 2005 Jun 13.
    PMID: 16160731 [PubMed - indexed for MEDLINE]
  16. Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C.
    Benefits of pamidronate in children with osteogenesis imperfecta: an open
    prospective study.
    Joint Bone Spine. 2005 Jul;72(4):313-8. Epub 2004 Dec 15.
    PMID: 16038843 [PubMed - indexed for MEDLINE]
  17. Rauch F, Glorieux FH.
    Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for
    how long?
    Ann Med. 2005;37(4):295-302. Review.
    PMID: 16019729 [PubMed - indexed for MEDLINE]
  18. Gatti D, Viapiana O, Lippolis I, Braga V, Prizzi R, Rossini M, Adami S.
    Intravenous bisphosphonate therapy increases radial width in adults with
    osteogenesis imperfecta.
    J Bone Miner Res. 2005 Aug;20(8):1323-6. Epub 2005 Mar 14.
    PMID: 16007328 [PubMed - indexed for MEDLINE]
  19. Morris CD, Einhorn TA.
    Bisphosphonates in orthopaedic surgery.
    J Bone Joint Surg Am. 2005 Jul;87(7):1609-18. Review.
    PMID: 15995133 [PubMed - indexed for MEDLINE]
  20. Iwamoto J, Takeda T, Sato Y.
    Efficacy of oral etidronate for skeletal diseases in Japan.
    Yonsei Med J. 2005 Jun 30;46(3):313-20. Review.
    PMID: 15988801 [PubMed - indexed for MEDLINE]
  21. Munns CF, Rauch F, Travers R, Glorieux FH.
    Effects of intravenous pamidronate treatment in infants with osteogenesis
    imperfecta: clinical and histomorphometric outcome.
    J Bone Miner Res. 2005 Jul;20(7):1235-43. Epub 2005 Feb 21.
    PMID: 15940378 [PubMed - indexed for MEDLINE]
  22. Forin V.
    [Osteogenesis imperfecta and bisphosphonates]
    Arch Pediatr. 2005 Jun;12(6):688-90. French. No abstract available.
    PMID: 15904772 [PubMed - indexed for MEDLINE]
  23. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill
    SC, Gerber LH, Marini JC.
    Controlled trial of pamidronate in children with types III and IV osteogenesis
    imperfecta confirms vertebral gains but not short-term functional improvement.
    J Bone Miner Res. 2005 Jun;20(6):977-86. Epub 2005 Jan 18.
    PMID: 15883638 [PubMed - indexed for MEDLINE]
  24. Shaw NJ, Bishop NJ.
    Bisphosphonate treatment of bone disease.
    Arch Dis Child. 2005 May;90(5):494-9. Review.
    PMID: 15851432 [PubMed - indexed for MEDLINE]
  25. Pizones J, Plotkin H, Parra-Garcia JI, Alvarez P, Gutierrez P, Bueno A, Fernandez-Arroyo A.
    Bone Healing in Children With Osteogenesis Imperfecta Treated With Bisphosphonates.
    J Pediatr Orthop. 2005 May/June;25(3):332-335.
    PMID: 15832149
  26. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S.
    Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    J Bone Miner Res. 2005 May;20(5):758-63. Epub 2004 Dec 20.
    PMID: 15824848
  27. Licata AA.
    Discovery, clinical development, and therapeutic uses of bisphosphonates.
    Ann Pharmacother. 2005 Apr;39(4):668-77. Epub 2005 Mar 8.
    PMID: 15755793
  28. Dimeglio LA, Ford L, McClintock C, Peacock M.
    A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
    J Pediatr Endocrinol Metab. 2005 Jan;18(1):43-53.
    PMID: 15679068 [PubMed - in process]
  29. Waltimo-Siren J, Kolkka M, Pynnonen S, Kuurila K, Kaitila I, Kovero O.
    Craniofacial features in osteogenesis imperfecta: a cephalometric study.
    Am J Med Genet A. 2005 Mar 1;133(2):142-50.
    PMID: 15666304
  30. Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP.
    Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
    Bone. 2005 Jan;36(1):150-8.
    PMID: 15664013
  31. Iwamoto J, Takeda T, Sato Y.
    Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report.
    Keio J Med. 2004 Dec;53(4):251-5.
    PMID: 15647630
  32. Adiyaman P, Ocal G, Berberoglu M, Evliyaoglu O, Aycan Z, Cetinkaya E.
    The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta.
    Turk J Pediatr. 2004 Oct-Dec;46(4):322-8.
    PMID: 15641265
  33. Popko J, Galicka A, Wolczynski S, Zalewski W, Konstantynowicz J.
    [Osteogenesis imperfecta as an interdisciplinary medical problem]
    Chir Narzadow Ruchu Ortop Pol. 2004;69(4):235-9. Polish.
    PMID: 15587378
  34. Bin-Abbas BS, Al-Ashwal AA, Al-Zayed ZS, Sakati NA.
    Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
    Saudi Med J. 2004 Nov;25(11):1772-3.
    PMID: 15573233
  35. Zacharin M, Kanumakala S.
    Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
    J Pediatr Endocrinol Metab. 2004 Nov;17(11):1511-7.
    PMID: 15570988
  36. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH.
    Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
    J Bone Miner Res. 2004 Nov;19(11):1779-86. Epub 2004 Aug 23.
    PMID: 15476577
  37. Munns CF, Rauch F, Ward L, Glorieux FH.
    Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.
    J Bone Miner Res. 2004 Oct;19(10):1742-5. Epub 2004 Jul 21.
    PMID: 15355570
  38. Boutaud B, Laville JM.
    [Elastic sliding central medullary nailing with osteogenesis imperfecta. Fourteen cases at eight years follow-up]
    Rev Chir Orthop Reparatrice Appar Mot. 2004 Jun;90(4):304-11. French.
    PMID: 15211258
  39. Rauch F, Travers R, Munns C, Glorieux FH.
    Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis.
    J Bone Miner Res. 2004 Jul;19(7):1191-3. Epub 2004 Jul 1.
    PMID: 15177003
  40. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C.
    Skeletal effects and functional outcome with olpadronate in children
    with osteogenesis imperfecta: a 2-year randomised placebo-controlled
    study.
    Lancet. 2004 May 1;363(9419):1427-31.
    PMID: 15121405
  41. Rauch F, Glorieux FH.
    Osteogenesis imperfecta.
    Lancet. 2004 Apr 24;363(9418):1377-85.
    PMID: 15110498
  42. Arikoski P, Silverwood B, Tillmann V, Bishop NJ.
    Intravenous pamidronate treatment in children with moderate to
    severe osteogenesis imperfecta: assessment of indices of dual-energy
    X-ray absorptiometry and bone metabolic markers during the first year
    of therapy.
    Bone. 2004 Mar;34(3):539-46.
    PMID: 15003801
  43. Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD.
    Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
    Pharmacotherapy. 2004 Feb;24(2):195-7.
    PMID: 14998220
  44. Niyibizi C, Wang S, Mi Z, Robbins PD.
    Gene therapy approaches for osteogenesis imperfecta.
    Gene Ther. 2004 Feb;11(4):408-16.
    PMID: 14724682
  45. Glorieux FH, Rauch F, Shapiro JR.
    Bisphosphonates in children with bone diseases.
    N Engl J Med. 2003 Nov 20;349(21):2068-71; author reply 2068-71.
    PMID: 14631922
  46. Plotkin H.
    Bisphosphonates in children with bone diseases.
    N Engl J Med. 2003 Nov 20;349(21):2068-71; author reply 2068-71.
    PMID: 14627793
  47. Tolboom N, Cats EA, Helders PJ, Pruijs JE, Engelbert RH.
    Osteogenesis imperfecta in childhood: effects of spondylodesis on
    functional ability, ambulation and perceived competence.
    Eur Spine J. 2004 Mar;13(2):108-13. Epub 2003 Nov 8.
    PMID: 14608498
  48. Ashford RU, Dey A, Kayan K, McCloskey EV, Kanis JA.
    Oral clodronate as treatment of osteogenesis imperfecta.
    Arch Dis Child. 2003 Oct;88(10):945.
    PMID: 14500323
  49. Davies JH, Gregory JW.
    Radiographic long bone appearance in a child administered cyclical pamidronate.
    Arch Dis Child. 2003 Oct;88(10):854.
    PMID: 14500300
  50. Kok DJ, Uiterwaal CS, Van Dongen AJ, Kramer PP, Pruijs HE, Engelbert RH, Verbout AJ, Schweitzer DH, Sakkers RJ.
    The interaction between Sillence type and BMD in osteogenesis imperfecta.
    Calcif Tissue Int. 2003 Nov;73(5):441-5. Epub 2003 Sep 10.
    PMID: 12958692
  51. Marini JC.
    Do bisphosphonates make children's bones better or brittle?
    N Engl J Med. 2003 Jul 31;349(5):423-6.
    PMID: 12890840
  52. Reid IR.
    Bisphosphonates: new indications and methods of administration.
    Curr Opin Rheumatol. 2003 Jul;15(4):458-63.
    PMID: 12819475
  53. Maasalu K, Haviko T, Martson A.
    Treatment of children with Osteogenesis imperfecta in Estonia.
    Acta Paediatr. 2003 Apr;92(4):452-5.
    PMID: 12801112
  54. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel
    M, Glorieux FH.
    Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.
    Pediatrics. 2003 May;111(5 Pt 1):e601-3.
    PMID: 12728117
  55. Zeitlin L, Rauch F, Plotkin H, Glorieux FH.
    Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
    Pediatrics. 2003 May;111(5 Pt 1):1030-6.
    PMID: 12728084
  56. Grissom LE, Harcke HT.
    Radiographic features of bisphosphonate therapy in pediatric patients.
    Pediatr Radiol. 2003 Apr;33(4):226-9. Epub 2003 Feb 15.
    PMID: 12709749
  57. Rauch F, Plotkin H, Zeitlin L, Glorieux FH.
    Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
    J Bone Miner Res. 2003 Apr;18(4):610-4.
    PMID: 12674321
  58. Evans KD, Lau ST, Oberbauer AM, Martin RB.
    Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.
    Bone. 2003 Mar;32(3):268-74.
    PMID: 12667554
  59. Iwamoto J, Matsu K, Takeda T, Ichimura S, Uzawa M.
    Effects of treatment with etidronate and alfacalcidol for osteogenesis imperfecta type I: a case report.
    J Orthop Sci. 2003;8(2):243-7.
    PMID: 12665966
  60. Chien YH, Chu SY, Hsu CC, Hwu WL.
    Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant.
    J Inherit Metab Dis. 2002 Nov;25(7):593-5.
    PMID: 12638943
  61. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH.
    Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.
    J Clin Endocrinol Metab. 2003 Mar;88(3):986-92.
    PMID: 12629073
  62. Langman CB.
    Improvement of bone in patients with osteogenesis imperfecta treated with pamidronate-lessons from biochemistry.
    J Clin Endocrinol Metab. 2003 Mar;88(3):984-5.
    PMID: 12629072
  63. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML.
    Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
    Pediatrics. 2003 Mar;111(3):573-8.
    PMID: 12612238
  64. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M.
    Use of bisphosphonate therapy for osteoporosis in childhood and
    adolescence.
    J Paediatr Child Health. 2003 Mar;39(2):88-92.
    PMID: 12603794
  65. Illum NO.
    [Bisphosphonate treatment of children and adolescents]
    Ugeskr Laeger. 2003 Jan 27;165(5):454-6. Danish.
    PMID: 12599842
  66. Zeitlin L, Fassier F, Glorieux FH.
    Modern approach to children with osteogenesis imperfecta.
    J Pediatr Orthop B. 2003 Mar;12(2):77-87.
    PMID: 12584489
  67. Camacho NP, Carroll P, Raggio CL.
    Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
    Calcif Tissue Int. 2003 May;72(5):604-9. Epub 2003 Feb 10.
    PMID: 12574874
  68. Yurekli Y, Erdogan S, Cullu E.
    Unusual bone scan of a child with osteogenesis imperfecta.
    Clin Nucl Med. 2003 Feb;28(2):156.
    PMID: 12544144
  69. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tato L.
    Intravenous neridronate in adults with osteogenesis imperfecta.
    J Bone Miner Res. 2003 Jan;18(1):126-30.
    PMID: 12510813
  70. Devogelaer JP.
    New uses of bisphosphonates: osteogenesis imperfecta.
    Curr Opin Pharmacol. 2002 Dec;2(6):748-53.
    PMID: 12482741
  71. Giraud F, Meunier PJ.
    Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
    Joint Bone Spine. 2002 Oct;69(5):486-90.
    PMID: 12477233
  72. Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, Santiago HT, Bober M.
    The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
    Calcif Tissue Int. 2003 Feb;72(2):103-12. Epub 2002 Dec 4.
    PMID: 12457260
  73. Banerjee I, Shortland GJ, Evans WD, Gregory JW.
    Osteogenesis imperfecta and intravenous pamidronate.
    Arch Dis Child. 2002 Dec;87(6):562-3.
    PMID: 12456578
  74. Rauch F, Travers R, Plotkin H, Glorieux FH.
    The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
    J Clin Invest. 2002 Nov;110(9):1293-9.
    PMID: 12417568
  75. Lindsay R.
    Modeling the benefits of pamidronate in children with osteogenesis imperfecta.
    J Clin Invest. 2002 Nov;110(9):1239-41.
    PMID: 12417561
  76. McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, Camacho NP.
    Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
    Pediatr Res. 2002 Nov;52(5):660-70.
    PMID: 12409511
  77. Kone Paut I, Gennari JM, Retornaz K, Jouve JL, Bollini G.
    [Biphosphonates in children: present and future]
    Arch Pediatr. 2002 Aug;9(8):836-42. French. Erratum in: Arch
    Pediatr. 2002 Dec;9(12):1301.
    PMID: 12205795
  78. Allgrove J.
    Use of bisphosphonates in children and adolescents.
    J Pediatr Endocrinol Metab. 2002;15 Suppl 3:921-8.
    PMID: 12199351
  79. Kaitila I, Kuurila K, Kallio P.
    [Osteogenesis imperfecta--a congenital brittleness of bones]
    Duodecim. 2001;117(21):2195-202. Finnish.
    PMID: 12184207
  80. Silverwood B.
    Osteogenesis imperfecta: care and management.
    Paediatr Nurs. 2001 Apr;13(3):38-42.
    PMID: 12025296
  81. Inoue N, Seino Y.
    [Osteoporosis in childhood]
    Nippon Rinsho. 2002 Mar;60 Suppl 3:315-22. Japanese.
    PMID: 11979924
  82. Astrom E, Soderhall S.
    Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
    Arch Dis Child. 2002 May;86(5):356-64.
    PMID: 11970931
  83. Zacharin M, Bateman J.
    Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
    J Pediatr Endocrinol Metab. 2002 Feb;15(2):163-74.
    PMID: 11874181
  84. Orcel P, Beaudreuil J.
    Bisphosphonates in bone diseases other than osteoporosis.
    Joint Bone Spine. 2002 Jan;69(1):19-27.
    PMID: 11858352
  85. Glorieux FH.
    The use of bisphosphonates in children with osteogenesis imperfecta.
    J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1491-5.
    PMID: 11837505
  86. Lee YS, Low SL, Lim LA, Loke KY.
    Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
    Eur J Pediatr. 2001 Nov;160(11):641-4.
    PMID: 11760017
  87. Vasikaran SD.
    Bisphosphonates: an overview with special reference to alendronate.
    Ann Clin Biochem. 2001 Nov;38(Pt 6):608-23.
    PMID: 11732644
  88. Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL.
    A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
    Calcif Tissue Int. 2001 Aug;69(2):94-101.
    PMID: 11683430
  89. Primorac D, Rowe DW, Mottes M, Barisic I, Anticevic D, Mirandola
    S, Gomez Lira M, Kalajzic I, Kusec V, Glorieux FH.
    Osteogenesis imperfecta at the beginning of boneand joint decade.
    Croat Med J. 2001 Aug;42(4):393-415.
    PMID: 11471191
  90. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J.
    Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.
    J Pediatr Endocrinol Metab. 2001 May;14(5):529-33.
    PMID: 11393574
  91. Chevrel G, Meunier PJ.
    Osteogenesis imperfecta: lifelong management is imperative and feasible.
    Joint Bone Spine. 2001 Mar;68(2):125-9.
    PMID: 11324928
  92. Guillot M, Eckart P, Desrosieres H, Amiour M, al-Jazayri Z.
    [Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report]
    Arch Pediatr. 2001 Feb;8(2):172-5. French.
    PMID: 11232458
  93. Smith R.
    Severe osteogenesis imperfecta: new therapeutic options?
    BMJ. 2001 Jan 13;322(7278):63-64.
    PMID: 11154605
  94. Antoniazzi F, Mottes M, Fraschini P, Brunelli PC, Tato L.
    Osteogenesis imperfecta: practical treatment guidelines.
    Paediatr Drugs. 2000 Nov-Dec;2(6):465-88.
    PMID: 11127846
  95. Byers PH.
    Osteogenesis imperfecta: perspectives and opportunities.
    Curr Opin Pediatr. 2000 Dec;12(6):603-9.
    PMID: 11106283
  96. Glorieux FH.
    Bisphosphonate therapy for severe osteogenesis imperfecta.
    J Pediatr Endocrinol Metab. 2000 Sep;13 Suppl 2:989-92.
    PMID: 11086652
  97. Devogelaer JP.
    Treatment of bone diseases with bisphosphonates, excluding osteoporosis.
    Curr Opin Rheumatol. 2000 Jul;12(4):331-5.
    PMID: 10910187
  98. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH.
    Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
    J Clin Endocrinol Metab. 2000 May;85(5):1846-50.
    PMID: 10843163
  99. Krassas GE.
    Idiopathic juvenile osteoporosis.
    Ann N Y Acad Sci. 2000;900:409-12.
    PMID: 10818429
  100. Srivastava T, Alon US.
    Bisphosphonates: from grandparents to grandchildren.
    Clin Pediatr (Phila). 1999 Dec;38(12):687-702.
    PMID: 10618761
  101. Roldan EJ, Pasqualini T, Plantalech L.
    Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients.
    J Pediatr Endocrinol Metab. 1999 Jul-Aug;12(4):555-9.
    PMID: 10417973
  102. Bishop NJ.
    Osteogenesis imperfecta calls for caution.
    Nat Med. 1999 May;5(5):466-7.
    PMID: 10229208
  103. Marini JC.
    Osteogenesis imperfecta--managing brittle bones.
    N Engl J Med. 1998 Oct 1;339(14):986-7.
    PMID: 9753715
  104. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R.
    Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    N Engl J Med. 1998 Oct 1;339(14):947-52.
    PMID: 9753709
  105. Devogelaer JP, Nagant de Deuxchaisnes C.
    Use of pamidronate in chronic and acute bone loss conditions.
    Medicina (B Aires). 1997;57 Suppl 1:101-8.
    PMID: 9567362
  106. Kodama H, Kubota K, Abe T.
    Osteogenesis imperfecta: Are fractures and growth hormone treatment linked?
    J Pediatr. 1998 Mar;132(3 Pt 1):559-60.
    PMID: 9544925
  107. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A.
    Intravenous pamidronate treatment in osteogenesis imperfecta.
    Eur J Pediatr. 1998 Mar;157(3):261-2.
    PMID: 9537501
  108. Astrom E, Soderhall S.
    Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta.
    Acta Paediatr. 1998 Jan;87(1):64-8.
    PMID: 9510450
  109. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G.
    Intravenous pamidronate treatment in osteogenesis imperfecta.
    J Pediatr. 1997 Oct;131(4):622-5.
    PMID: 9386671
  110. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE.
    Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).
    Eur J Pediatr. 1997 Oct;156(10):792-4.
    PMID: 9365071
  111. Moriwake T, Seino Y.
    Recent progress in diagnosis and treatment of osteogenesis imperfecta.
    Acta Paediatr Jpn. 1997 Aug;39(4):521-7.
    PMID: 9316304
  112. Brumsen C, Hamdy NA, Papapoulos SE.
    Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis.
    Medicine (Baltimore). 1997 Jul;76(4):266-83.
    PMID: 9279333
  113. Shaw NJ.
    Bisphosphonates in osteogenesis imperfecta.
    Arch Dis Child. 1997 Jul;77(1):92-3.
    PMID: 9279168
  114. Chevrel G, Meunier PJ.
    Are drugs helpful in adults with osteogenesis imperfecta?
    Rev Rhum Engl Ed. 1997 May;64(5):283-6.
    PMID: 9190000
  115. Williams CJ, Smith RA, Ball RJ, Wilkinson H.
    Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.
    Arch Dis Child. 1997 Feb;76(2):169-70.
    PMID: 9068314
  116. Cherie-Ligniere G, Tamborini U, Grosso P.
    Algodystrophy in conjunction with van der Hoeve's syndrome.
    Clin Exp Rheumatol. 1995 May-Jun;13(3):361-5.
    PMID: 7554566
  117. Laroche M, Dromer C, Jacquemier JM, Mazieres B, Arlet J.
    [The association of algodystrophy and Lobstein's disease. Possible value of 3-amino-1-hydroxypropane-1,1-diphosphonic acid]
    Rev Rhum Mal Osteoartic. 1990 Mar;57(3):221-2. French.
    PMID: 2339269
  118. Burke TE, Crerand SJ, Dowling F.
    Hypertrophic callus formation leading to high-output cardiac failure in a patient with osteogenesis imperfecta.
    J Pediatr Orthop. 1988 Sep-Oct;8(5):605-8.
    PMID: 3170743
  119. Huaux JP, Lokietek W.
    Is APD a promising drug in the treatment of severe osteogenesis imperfecta?
    J Pediatr Orthop. 1988 Jan-Feb;8(1):71-2.
    PMID: 3335625
  120. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C.
    Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.
    Skeletal Radiol. 1987;16(5):360-3.
    PMID: 3629280
  121. Kramer EL, Rafii M, Fazzini E, Sanger J.
    Bone scan appearance of osteogenesis imperfecta in an adult.
    Clin Nucl Med. 1986 May;11(5):331-3.
    PMID: 3698431

Δείτε επίσης: Abstracts από μερικά άρθρα για τη χρήση του Pamidronate στα παιδιά με ατελή οστεογένεση